BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Ka Pipeline Programs
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Ka Breaker, at the San Antonio Breast Cancer Symposium (SABCS)